One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The handbook includes historical dosing below GFR 15 and during dialysis. The selected U.S. adult tablet label does not recommend use below eGFR 15 or during hemodialysis; the handbook is not an override.
Use adult MDRD eGFR in mL/min/1.73 m2. Pediatric tablets and granules have different tables.
What to reconcile: Apply only to the stated formulation, indication and renal population.
Open this note and its source referencesDialysis evidence: Use is not recommended / excluded in the named dialysis population; not a dialysis dose
Use adult MDRD eGFR in mL/min/1.73 m2. Pediatric tablets and granules have different tables.
| Adult eGFR (mL/min/1.73 m2) | Oral starting dose once daily | Maximum once daily |
|---|---|---|
| 30-89 | 25 mg | 50 mg |
| 15-29 | 25 mg | 25 mg |
| <15 or on dialysis | Use not recommended | Use not recommended |
At eGFR 30-89, start 25 mg once daily, maximum 50 mg daily. At 15-29, use 25 mg daily as both starting dose and maximum. Below 15 or on dialysis, use is not recommended. Use adult MDRD eGFR in mL/min/1.73 m2. Pediatric tablets and granules have different tables.
RDM73-myrbetriq-official-1 · Source locator: Renal guidance: 2.4, adult Table 2 and 8.6
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=general-mirabegron&s1=RDM73-myrbetriq-official&h1=ab842672a64504006a42cfa6f3350a9d73d41f1bae92fae406b362b5d79b5923